Comparative Pharmacology
Head-to-head clinical analysis: STAPHCILLIN versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAPHCILLIN versus UNIPEN.
STAPHCILLIN vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
1-2 g IV every 4-6 hours.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic